Home  »  Hot Stocks   »  We Analyzed the Future Direction of BridgeBio Phar...

We Analyzed the Future Direction of BridgeBio Pharma Inc. (BBIO), Here is What We Found

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

BridgeBio Pharma Inc. (NASDAQ:BBIO) went up by 0.63% from its latest closing price compared to the recent 1-year high of $73.50. The company’s stock price has collected -12.22% of loss in the last five trading sessions. Press Release reported 2 hours ago that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. – BBIO

Is It Worth Investing in BridgeBio Pharma Inc. (NASDAQ :BBIO) Right Now?

Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for BridgeBio Pharma Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The average price from analysts is $27.40, which is $13.1 above the current price. BBIO currently public float of 97.40M and currently shorts hold a 12.62% ratio of that float. Today, the average trading volume of BBIO was 3.18M shares.

BBIO’s Market Performance

BBIO stocks went down by -12.22% for the week, with a monthly drop of -60.49% and a quarterly performance of -69.34%, while its annual performance rate touched -79.17%. The volatility ratio for the week stands at 8.22% while the volatility levels for the past 30 days are set at 10.45% for BridgeBio Pharma Inc.. The simple moving average for the period of the last 20 days is -44.99% for BBIO stocks with a simple moving average of -71.42% for the last 200 days.

Analysts’ Opinion of BBIO

Many brokerage firms have already submitted their reports for BBIO stocks, with SVB Leerink repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to SVB Leerink is $24 based on the research report published on December 27th of the previous year 2021.

Mizuho, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $25, previously predicting the price at $86. The rating they have provided for BBIO stocks is “Buy” according to the report published on December 27th, 2021.

BofA Securities gave a rating of “Buy” to BBIO, setting the target price at $75 in the report published on September 10th of the previous year.

BBIO Trading at -61.46% from the 50-Day Moving Average

After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.54% of loss for the given period.

Volatility was left at 10.45%, however, over the last 30 days, the volatility rate increased by 8.22%, as shares sank -62.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -71.04% lower at present.

During the last 5 trading sessions, BBIO fell by -12.22%, which changed the moving average for the period of 200-days by -74.96% in comparison to the 20-day moving average, which settled at $24.81. In addition, BridgeBio Pharma Inc. saw -14.27% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BBIO starting from Dachille Douglas A., who purchase 5,000 shares at the price of $15.91 back on Jan 05. After this action, Dachille Douglas A. now owns 10,000 shares of BridgeBio Pharma Inc., valued at $79,550 using the latest closing price.

Dachille Douglas A., the Director of BridgeBio Pharma Inc., purchase 5,000 shares at $16.82 during a trade that took place back on Jan 04, which means that Dachille Douglas A. is holding 5,000 shares at $84,100 based on the most recent closing price.

Stock Fundamentals for BBIO

Current profitability levels for the company are sitting at:

  • -5751.99 for the present operating margin

The net margin for BridgeBio Pharma Inc. stands at -5439.74. The total capital return value is set at -80.46, while invested capital returns managed to touch -85.58. Equity return is now at value 138.60, with -58.50 for asset returns.

Based on BridgeBio Pharma Inc. (BBIO), the company’s capital structure generated 856.19 points at debt to equity in total, while total debt to capital is 89.54. Total debt to assets is 70.47, with long-term debt to equity ratio resting at 847.12. Finally, the long-term debt to capital ratio is 88.59.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 34.77, with the company’s debt to enterprise value settled at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.72.

Leave a Comment

Your email address will not be published. Required fields are marked *




Download Free eBook For


100% free. stop anytime no spam